Pfizer launches new Rimegepant oral medication in India for rapid migraine relief and acute treatment

Global pharmaceutical company Pfizer has announced the launch of a Rimegepant Orally Disintegrating Tablet (ODT) in India for acute treatment of migraine in adults with a previous insufficient response to triptan.

“The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. It also enables early return to function and sustained relief from most bothersome symptoms. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water,’’ said a statement released by the Company.

It added that by targeting one of the key elements of migraine’s pathophysiology – calcitonin gene-related peptide (CGRP) – this medication offers prompt and effective relief.

Meenakshi Nevatia, MD, Pfizer Ltd., India, said “We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options.”